DHFR and TYMS were the early enzymes of one-carbon metabolism to be clinically validated as targets for cancer therapy and remain the most successful in this context to date, and almost all Food and Drug Administration (FDA)-approved DHFR and TYMS inhibitors are classical or non-classical folate derivatives [178]. The gene discussed is DHFR; the disease is cancer.